Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

UpSMART aims to improve experimental cancer research across the UK, Italy & Spain.

During the COVID-19 pandemic, it became clear how important being digital is for our Early Phase Clinical Trials Units. Participating in initiatives like UpSMART is accelerating our digitalization and paving the way to implementing the use of medical devices in our trials.

Dr Elena Garralda

Spain Principal Investigator, UpSMART Accelerator Award, Vall d’Hebron Institute of Oncology, Barcelona, Spain

UpSMART has created open source digital healthcare products to improve experimental cancer research. The UpSMART team have worked with clinicians to address unmet clinical needs and develop our portfolio of 7 DHPs.

We are looking for collaborators who are interested in using these DHPs in research studies, please contact us if you are interested in working with us.

Digital Healthcare Product Portfolio

DESIGN

Clinical design and set up

P1PO

An online tool that can be used as an objective way for predicting overall survival outcomes in patients prior to enrolment on early phase clinical trials. It provides an individualized prediction of the survival time based on patients’ baseline analytical values.

Cancer Trial Finder Template

Displays all recruiting clinical trial options to members of the local clinical research team thus improving awareness to clinical research staff as to open clinical studies, thereby improving opportunities for patients’ access to clinical trials.

Coronet

A web-based decision support tool which allows clinicians to enter physiological criteria and based on a machine learning algorithm provides a likelihood of whether a cancer patient presenting with COVID-19 symptoms will require hospital admission.

DELIVERY

Process clinical trial monitoring, supporting patient identification, consent, feedback and reported outcomes.

Cancer Trial Matching Tool

System to help clinicians identify the right clinical trials for patients. It integrates a patient’s cancer type and tumour genotype with ClinicalTrials.gov and other online data sources to return a list of potential matching trials.

PROACT 2.0

Patient Reported Opinions About Clinical Tolerability – PROACT 2.0 is an open-source patient application for secure, direct communication between clinical trial participants and their medical team​.

INTERPRETATION

Clinical trial data analysis and supporting data capture.

Protocol Deviation Monitoring

A DHP powered by Natural Language Processing (NLP) enabling clinical professionals to categorise protocol deviations (PD) generating a detailed visualisation suite at both the individual site and study level allowing trends in PD data to be monitored.  It aligns with real-world clinical needs, featuring an intuitive interface and targeted functionality to allow PD trends to be effectively monitored, ultimately impacting improvements to data integrity, patient safety, and trial efficiencies.

eTARGET

A paperless decision-support system integrating the patient’s genomic profile with their clinical characteristics.  Used as part of a monthly Molecular Tumour Board.

Acuity

Interactive set of visualisations for clinical trial data which has been entered into the clinical trial database; for data interpretation at both the population and patient level to enable an earlier understanding of patient benefit-risk profile.

Why Upsmart?

Early phase trials are challenging as there is the need to analyse large volumes of data in real time as dose decisions are made. Through work package 2 we are exploring the utility of digital technology to improve this process. The release of a free to use version of ACUITY, a DHP to allow visualisation of trial data has been a significant milestone for the accelerator to meet this aim.

Dr Louise Carter

Senior Clinical Lecturer in Experimental Cancer Medicine. Honorary Consultant in Medical Oncology

QUICK LINKS

Home

About

Disclaimer: The digital health products created through UpSMART are for research use only as regulatory approval has not yet been sought. Please contact us if you wish to use any of the UpSMART products in a research study.

CONTACT

Digital Cancer Research team,

Cancer Research UK Manchester Institute

The University of Manchester

Wilmslow Road

Manchester

M20 4BX

DCR@CRUK.manchester.ac.uk